Literature DB >> 10658174

Myoadenylate deaminase deficiency. A common inherited defect with heterogeneous clinical presentation.

R L Sabina1.   

Abstract

Myoadenylate deaminase deficiency is a clinically heterogeneous metabolic disorder that is commonly diagnosed in a variety of neurologic settings. Although the molecular basis for this purine nucleotide catabolic derangement may typically be attributed to the inheritance of a single prevalent mutant allele, the clinical spectrum in the absence of other definable abnormalities can range from asymptomatic to mild exercise-induced myalgia. Moreover, myoadenylate deaminase deficiency is also found associated with other definable neuromuscular disorders. The myoadenylate deaminase deficiency in these latter cases may, in part, be precipitated by pathologic change or act synergistically in combination with another metabolic disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10658174     DOI: 10.1016/s0733-8619(05)70184-5

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  6 in total

Review 1.  The clinical laboratory evaluation of the patient with noninflammatory myopathy.

Authors:  R L Wortmann; G D Vladutiu
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 2.  Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction.

Authors:  Josef Finsterer
Journal:  Pediatr Cardiol       Date:  2009-01-29       Impact factor: 1.655

3.  Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency.

Authors:  S E Olpin; A Afifi; S Clark; N J Manning; J R Bonham; A Dalton; J V Leonard; J M Land; B S Andresen; A A Morris; F Muntoni; D Turnbull; M Pourfarzam; S Rahman; R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

4.  AMPD1 polymorphism and response to regadenoson.

Authors:  Rayan Saab; Aline N Zouk; Ronald Mastouri; Todd C Skaar; Santosh Philips; Rolf P Kreutz
Journal:  Pharmacogenomics       Date:  2015-11-10       Impact factor: 2.533

5.  Daily supplementation of D-ribose shows no therapeutic benefits in the MHC-I transgenic mouse model of inflammatory myositis.

Authors:  William Coley; Sree Rayavarapu; Jack H van der Meulen; Ayyappa S Duba; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

6.  Genetic test for Mendelian fatigue and muscle weakness syndromes.

Authors:  Aysha Karim Kiani; Bruno Amato; Silvia Maitz; Savina Nodari; Sabrina Benedetti; Francesca Agostini; Lorenzo Lorusso; Enrica Capelli; Astrit Dautaj; Matteo Bertelli
Journal:  Acta Biomed       Date:  2020-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.